A Study of Botensilimab and Balstilimab for the Treatment of Colorectal Cancer
Study sponsor: Agenus Inc. · AGEN
Primary completion is the date data collection ends for the main study measures, not when results are published.
Primary completion2027-09Estimated
Enrollment · participants234Actual
Source updated2026-11-05Last update listed in the registry record
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.